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Abstract. Introduction: Sentinel lymph node biopsy (SLNB) is accepted as a substitute method for axillary staging instead 
of axially lymph node dissection in patients with negative lymph node. The NSLN involvement is correlated with primary 
tumor and SLN characteristics. So, the diagnosis of the patients with lower risk of NSLN metastasis will save them from 
axillary lymph node dissection (ALND)-related morbidities.  This study aimed to determine the predictive factors for NSLN 
involvement in breast cancer patients with positive SLN. Materials and Methods: This cross-sectional study was 
performed on 482 patients with breast cancer and SLN involvement, referring to Rasoul Akram and Khatam-al-Anbia 
Hospital hospitals, Tehran, Iran, during 2010-2017. 6 hours up to one day before the surgery, the patients received a 
periareolar injection of radioactive materials. Then, all hot lymph nodes with suspected cancer invasion were resected. The 
SLN  radionuclide-avid were subjected to frozen section analysis. Axillary dissection was performed if metastases or even 
micrometastases were reported in nodes. Results: Overall, 66.5% and 33.5% of the patients had positive and negative 
SLNs, respectively. The results showed a significant relationship between lymph node involvement in the patients with 
breast cancer and SLN in term of non-SLN invasion (χ2=4.62; P<0.005).  There was also a significant relationship with 
lymphovascular invasion (LVI) (χ2=107.4; P<0.005), perineural involvement (χ2=32.27; P<0.005), and extra capsular 
lymph node involvement (χ2=48.01; P<0.005). 59.3% of the patients with negative HER2-enriched (16 out of 27 cases) had 
lymphovascular involvement.  there was no significant relationship between positive/negative Ki67 with gender and age 
(P>0.005). Conclusion: As the findings indicated, the patients with involved lymph node, a tumor size of > 2 cm, and high 
tumor stage have a significantly higher probability of metastasis progression to NSLN; therefore, they are suggested to 
undergo ALND. 
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Introduction. The SLNB is the standard of care for the axillary staging of breast cancer with negative node [1]. Today, 
breast cancer screening methods contribute to the early diagnosis of lymph node involvement prior to clinical examinations. 
Axillary dissection provides data about axillary node involvement and is considered as a trustable marker for the prediction 
of the prognosis and staging of breast cancer [1]. However, this approaches accompanied by some complications, such as 
seroma, lymph edema, and shoulder function disruption, in 6-30% of patients. In 1991, sentinel lymph node biopsy (SLNB) 
was accepted as an alternative method for axillary staging in patients with negative lymph node [2].  
Based on the evidence, in 40-70% of breast cancer patients, SLNs are the only involved nodes without the interference of 
non-sentinel lymph nodes (NSLNs) [3]. The node-negative breast cancer patients undergo axillary lymph node dissection 
(ALND) without gaining any benefits or obtaining data on their disease prognosis; moreover, they are affected by surgical 
complications [4]. The diagnosis of the patients with lower risk of NSLN metastasis will save them from ALND-related 
morbidities. The NSLN involvement is correlated with primary tumor and SLN characteristics [5].  
Breast cancer surgeries can even facilitate the reduction of primary tumor with lymphatic invasion. Many researchers 
suggest nomograms and scoring systems (with the factors affecting tumor and sentinel node) for the prediction of NSLN 
metastasis probability. Some of the most widely used methods in this regard include Memorial Sloan Kettering Cancer 
Center (MSKCC)[6], Cambridge [7], Stanford [7], and Ten on [8] nomograms, as well as Anderson Cancer Center scoring 
[9]. With this background in mind, the present study aimed to determine the predictive factors for NSLN involvement in 
breast cancer patients with positive SLN. 
Materials and Methods 
This descriptive cross-sectional study was conducted on breast cancer patients with SLN involvement during 2010-2017. 
Out of 1,605 patients with breast cancer referring to Rasol-e Akram and Khatam-al-Anbia hospitals in Tehran, Iran, 505 
cases with ultrasonography and clinical diagnosis of axillary lymph node involvement were subjected to ALND. The rests 
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of the patients (n=1,080) underwent SLN biopsy, 482 (481 females and 1 male) cases of whom who had positive axillary 
lymph node were included in the study.   
The data recorded for each patient included age, cancer stage, histology, multifocality, lymphovascular invasion (LVI), 
invasion to capsule, SLN size, SLN count, estrogen receptor, progesterone receptor, and NSLN involvement. The patients 
received a periareolar injection of radioactive materials 6hours uo to one day before the surgery. Then, all hot lymph nodes 
with suspected cancer invasion were subjected to resection. Then The SLN were subjected to frozen section analysis. 
Axillary dissection was performed in case metastases or even micrometastases were reported in those nodes. 
Statistical analysis 
The normally and non-normally distributed variables were analyzed using t-test and Mann Whitney U test, respectively. 
Furthermore, the Chi-square test or Fisher’s exact test was adopted to analyze the qualitative variables. Multivariate logistic 
regression analysis was run for confounding data expressed in odds ratio. The analysis of the relationship between variables 
was accomplished through Pearson and Spearman’s rank order correlation coefficients. All data analyses were performed in 
SPSS, version 22.P-value less than 0.05 was considered statistically significant. 
Results 
Based on the obtained results, 99.6% of the patients were female. The mean age of the participants was obtained as 
52.06±11.5 years (age range: 13-86 years). Furthermore, 1.5%, 42.6%, 47.9, and 8% of the patients were in the age groups 
of < 30, 30-49, 50-69, and ≥ 70 years respectively. The mean tumor size was 2.72±1.52 cm, and the mean number of 
positive lymph nodes was 2.59±4.64. Moreover, the mean number of lymph nodes was 9.31±6.18, which ranged within 0-
33.  
Overall, 66.5% and 33.5% of the patients had positive and negative SLNBs, respectively. The non-specified tumor was the 
most common type of tumors as observed in 62.7% (n=1,007) of the patients. Furthermore, classic tumor was the second 
common tumor type, which was observed in 9.8% (n=158) of the patients. Invasive ductal carcinoma (IDC) was the most 
commonly diagnosed pathology (58.7%) in breast cancer patients with SLN involvement, followed by IDC plus DCIS and 
invasive lobular carcinoma (ILC), respectively. 480 cases (56.8%) were positive in term of Ki67 while 365 ones (43.2%) 
were negative (table 1). 
 
Table 1. Tumor characteristics 
Variables  No Percen
t  







MRM* 324 20.5 Unclear 23 5.6 
Breast preserving 1178 74.7 Not done 186 45.1 
Tumor 
grade  
None 53 3.5 Free 157 38.1 
One  128 8.5 Residual breast 
cancer 
yes 15 4.4 
Two 721 48 Unclear 52 15.1 
Three  601 40 Not done 186 54.1 
Nuclear 
grade 
None 157 10.9 Free 91 26.5 
One  29 2.0 Fine needle 
aspiration 
No 42 2.7 
Two 208 14.4 yes 1381 90.1 
Three  1051 72.7 Unclear 110 7.2 
Multicentri
c tumors 









No 1228 80.0 Right 781 49.6 
Yes 253 16.5 Neoadjuvant 
therapy 
No 1351 90.9 




No 965 62.0 Type of diagnosis Unclear 57 3.7 
Yes 557 35.8 Open biopsy 51 3.3 
Unclear  34 2.2 frozen 268 17.4 
Calcificatio
n  
No 1184 77.4 FNA 10 0.6 
Yes 250 16.3 Core biopsy 1155 75 
Necrosis No 1010 66.1 P53 Ser
1 67 15 
Yes 424 27.7 Ser
6 242 54 
Unclear 94 6.2 Ser
9 139 31 
Stage of 
cancer 
0 10 0.9 Tumor/node/meta
stasis  
T0 10 0.9 
1 252 23.5 T1N0 226 21.4 
2A 325 30.3 T1N1 80 7.6 
2B 172 16.1 T1N2 33 3.1 
3A 144 13.4 T1N3 13 1.2 
3B 28 2.6 T2N0 270 25.6 
3C 124 11.6 T2N1 162 15.3 
4 16 1.5 T2N2 107 10.1 
Ki67 Yes  480 56.8 T2N3 49 4.6 
No 365 43.2 T3N0 31 2.9 
ER* Positive  960 65.4 T3N1 20 1.9 
Unclear  135 9.2 T3N2 20 1.9 
Negative 373 25.4 T3N3 26 2.5 
Sentinel Positive  1011 66.5 T4N1 2 0.2 
Negative  509 33.5 T4N2 3 0.3 
HER2** Positive  155 10.7 T4N3 4 0.4 
Unknown 150 10.4 PR*** Positive  940 64.1 
Negative  1141 78.9 Unknown 131 8.9 
   Negative  395 26.9 
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* Estrogen-Receptor ** Human Epidermal Growth Factor Receptor 2*** Progesterone-Receptor 
 
The results also demonstrated a significant relationship between lymph node involvement in the patients with breast cancer 
and SLN in terms of extra capsular lymph node involvement (χ2=1.36; P<0.005), size (χ2=3.67; P<0.005), 
multifocality/multicentricity (χ2=33.21; P<0.005), number of lymph nodes (χ2=5.68; P<0.005), invasion grade (χ2=2.47; 
P<0.005), non-SLN invasion (χ2=4.62; P<0.005), lymphatic system invasion (χ2=1.82; P<0.005), histological condition 
(χ2=1.21; P=0.004), and pathology of tumor (χ2=1.53; P<0.005). 
Table 2 demonstrates the comparison of patients with different age groups and genders in terms of various tumor 
characteristics. 
 
Table 2: Comparison of patients with different age groups and genders in terms of various tumor characteristics 
 Age  Gender 
Variables  χ2  P-value χ2 P-value 
Tumor grade 15.36 0.08 0.89 0.83 
Nuclear grade 13.69 0.32 1.27 0.86 
Tumor size 11.48 0.24 0.54 0.9 
Being multifocal/multicentric 5.58 0.13 0.27 0.59 
Number of lymph nodes 1.43 0.007 61.3 0.004 
ER* 12.56 0.05 7.89 0.9 
PR** 6.64 0.35 4.09 0.53 
HER*** 3.74 0.71 1.78 0.77 
Ki 67 5.85 0.11 5.6 0.58 
Invasion grade  56 0.12 15.73 0.4 
 ExCLNI****  70.57 0.78 38.81 0.084 
Non-SLN invasion  6.82 0.96 4.44 0.48 
Histological condition  43.8 0.27 9.107 0.69 
Lymphatic System Invasion 8.17 0.22 1.46 0.48 
Stage  26.904 0.17 5.6 0.58 
* Estrogen-receptor; ** Progesterone receptor;*** Human epidermal growth factor receptor; **** Extra capsular lymph 
node involvement  
In our study, the majority of the breast cancer cases were identified as luminal A group. Table 3 presents the percentage of 
tumor involvement in four subtype groups of positive or negative sentinel and non-sentinel nodes.  Positive and negative 
SLNs showed a significant relationship with LVI (χ2=107.4; P<0.005), perineural involvement (χ2=32.27; P<0.005), and 
capsular lymph node involvement (χ2=48.01; P<0.005). The LVI possibility was higher in negative human epidermal 
growth factor receptor 2(HER2)-enriched type compared with the other groups. The comparison of the HER2-enriched 
group with other three groups revealed that 59.3% (16 out of 27 patients) of the patients with no HER2-enriched had 
lymphovascular involvement. Based on the results, there was no significant difference among the subtypes (i.e., luminal A, 
luminal B/HER2 positive, HER2-enriched type, and triple negative) in terms of LVI (χ2=9.75; P=0.13). 
 
Table 3: Percentage of tumor involvement  in four subtype groups of positive or negative sentinel and non-sentinel nodes 
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 Luminal A Luminal B/HER2 
positive 
HER2 enrich Triple negative 
Subtype groups No  Percent  No  Percent  No  Percent  No  Percent  
LVI* No 360 63.9 40 66.7 11 40.7 102 68.0 
Yes 198 35.2 20 33.3 16 59.3 48 32.0 





85.5 45 78.9 20 74.1 132 89.2 
Yes  68 12.3 12 21.1 7 25.9 15 10.1 
Unclear  12 2.2 -- -- -- -- 1 0.7 
Tumor grade  0 5 0.9 -- -- -- -- -- -- 
1 62 11.2 3 5.2 1 4.0 7 5.0 
2 320 57.6 17 29.3 11 44.0 44 31.2 
3 169 30.4 38 65.5 13 52.0 90 63.8 
* lymphovascular invasion 
 
Discussion 
In the present study, out of the patients with negative SLNB report undergoing axillary dissection based on the surgeon’s 
decision by NSLN palpation and professionalism, five patients had positive lymph nodes, and the rate of false-negative 
SLNB was obtained as 0.8%. Some causes of false-negative results could be: 
-Tissue attenuation and shine-through effect from the injection site 
-Delayed tracer migration due to obesity or elderliness (that could be due to the increased fatty tissue with impending the 
flow of the tracer through the lymphatic or fatty degeneration of LNs reducing their capacity to concentrate the tracer) 
-Pathologic examination of the samples to detect more micrometastasis and isolated tumor cells 
It is supposed that after the lodging of tumor cells in sentinel nodes, the node losses its function; thereafter, venous drainage 
will bypass the involved SLN and reach a new lymph node (i.e., NSLN). Therefore, it is supposed that NSLN metastasis is 
detected, along with SLN metastasis. The majority of our patients had both NSLN and SLN involvement.Estrogen and 
progesterone receptors have been observed in tumor cells the growth of which depends on estrogen and progesterone. The 
evaluation of these receptors can help the doctors to choose between hormonal treatment or other treatments. Hormonal 
treatment includes the administration of drugs to reduce estrogen level in body or stop the estrogen impact on the growth 
and function of the breast tumor cells. The presence of at least one kind of these receptors in tumor cells would result in a 
very good response to hormone therapy. Regarding this, proving of existence of these receptors would contribute to the 
estimation of the disease prognosis and treatment success. 
Our study indicated that 56.8% of tumors were positive in term of Ki67. According to Colleoni et al., PR, ER, and Ki67 
receptors are more common in breast cancer, occurring in younger ages, and more invasive types[10]. Ki67 is a predictive 
marker of a patient’s response to chemotherapy in those with lymph node non-involvement and early-diagnosed cancers. 
Another marker that was evaluated in this study was HER2. This marker was positive in just 14% of our patients with 
positive SLN. This is in line with the results reported in another study conducted with the purpose of determining the factors 
responsible for cancers occurring at young age and cancers of poor prognosis in the recurrence and invasion rate of which 
HER2 plays no role [10-12].  
In our data analysis, a higher axillary node involvement showed a significant relationship with cancer stage, mass size (with 
a cut off value of2cm), and investigated biomarkers (i.e., PR, ER, and Ki67). Furthermore, there was a direct relationship 
between P53, HER2, tumor grade, vascular invasion, positive margins, and tumor subtypes. Additionally, an indirect 
relationship was observed between calcification rate, neoadjuvant therapy, and multi; however, this relationship was not 
statistically significant. 
Based on the ROC curve analysis with a cut off value of30%, a significant relationship was obtained between Ki67 and 
axillary node involvement. Totally, ALND is necessary in cases with axillary node involvement; nonetheless, we should not 
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candidate patients with lower risk of axillary node involvement for this invasive surgery due to such complications as 
edema, pain, and swelling of the lower limb. 
 
Positive NSLN is associated with primary tumor size, the biggest SLN metastasis size, and lymphovascular aggression. 
Several studies have investigated the factors predicting SLN involvement in metastatic breast cancer patients [9]. Barranger 
et al. evaluated predictive factors for SLN involvement in the majority of the women undergoing axillary lymph node 
(ALND). Mono-variable analysis showed a significant relationship between NSLN involvement and primary histological 
tumor size, SLN macro-metastasis, diagnostic method of SLN metastasis, number of SLN-positive cases, SLN involvement 
cases, and LVI [8].  
Gunay et al. reported that the risk of metastasis to NSLN is very low when SLN is free of tumor. They also revealed that 
peritumoral LVI and tumor size of> 2cm significantly increase the probability of NSLN metastasis. Overall, it is obvious 
that the patients with no SLN metastasis has a very good prognosis (close to that of the normal population). However, this 
prognosis is lower than that of the patients with LVI. In addition, LVI and tumor size of> 2cm were reported as the most 
important factors affecting NSLN metastasis. It is probable to have false-negative lymphoscintographic results for SLN 
metastasis in cases with NSLN involvement. Therefore, even negative-SLN patients with LVI and tumor size of > 2cm can 
take benefits of ALND because according to studies, they have axillary lymph node involvement [13]. 
Previously, the determination of lymph node involvement was accomplished by using ALND. Nonetheless, currently, 
SLNB is adopted to this end as the most standard and complication-free method. The SLNB is mostly used in recently 
diagnosed cancers and facilitates the evaluation of axillary lymph node involvement prior to the surgery, as well as the 
selection of the best surgical method [14,15]. In order to identify these factors and a tool to determine metastasis possibility 
in NSLN, some centers, such as MD Anderson cancer center, designed a nomogram that predicts the metastasis in NSLN. 
According to their view, the determining factors include the primary tumor size, histology, LVI, involved SNL number, 
metastasis size, and extracapsular invasion. Another nomogram has been designed by the MSKCC considering some 
factors, such as tumor size, LVI, assessment method, and number of positive nodes [16].  
 
Edward et al. used a combined blue dye SLNB/ANS technique and reported positive SLN in 98.3% of cases. However, 
axillary NSLN metastasis was observed in few cases without SLN involvement [17]. In another study, Nowikiewicz et al. 
investigated the NSLN metastasis rate in patients with SLN involvement using artificial neural network. They reported SLN 
metastasis size asthe most important risk factor in this regard. In the mentioned study, the possibility of NSLN involvement 
in isolated tumor cells in SLN was obtained as4.7%, while this rate was estimated as 42%in SLN micrometastasis cases[18]. 
Not being SLNB-positive is not necessarily mean no metastasis to NSLN; however, residual disease will not affect the 
disease survival or recurrence [16].  
After histochemical evaluation, it could be possible for patients with negative lymphoscintography SLNB to have no need 
to AD. There is a very low probability of NSLN involvement before SLN involvement; accordingly, surgeons need an 
algorithm to determine the NSLN involvement risk. Given the possibility of obtaining false-negative results for SLNB, it is 
essential to detect patients with a higher probability of having positive NSLN findings to prevent the recurrence caused by 
the remained positive posterior axillary nodes, which are not carefully explored (because of trusting the negative SLNB 
result) [14].  
Conclusion 
As the findings indicated, SLNB and evaluation of the factors determining NSLN involvement probability would facilitate 
the selection of the best therapeutic method. Moreover, these measures would save the patients with lower axillary node 
metastasis risk from the complications caused by undergoing ALND. Out of the biomarkers evaluated in this study, Ki67, 
ER, and PR showed a significant relationship with more invasions to lymph nodes. Nonetheless, HER2 and P53 markers 
demonstrated no significant relationship with the mentioned variable. According to our results, the patients with involved 
lymph node, tumor size of > 2cm, and high tumor stage had a significantly higher probability of the progression of the 
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